Overview

In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy

Status:
Recruiting

Trial end date:
2024-04-01

Target enrollment:

Participant gender:

Summary

This phase 2 randomised clinical trial will compare the effectiveness of Lu-PSMA therapy followed by docetaxel chemotherapy versus docetaxel chemotherapy on its own in patients with newly-diagnosed high-volume metastatic hormone-naive prostate cancer (mHNPC).

Phase:

Phase 2

Details

Lead Sponsor:

Peter MacCallum Cancer Centre, Australia

Collaborators:

Advanced Accelerator Applications
Australasian Radiopharmaceutical Trials network (ARTnet)
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Australian Nuclear Science and Technology Organisation (ANSTO)
Centre for Biostatistics and Clinical Trials (BaCT)
Movember Foundation
Prostate Cancer Research Alliance
United States Department of Defense

Treatments:

177Lu-PSMA-617
Docetaxel